This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The active ingredients in those drugs also are approved for other conditions, including diabetes and cardiovascular disease, that Medicare does cover. The Congressional Budget Office estimates that 29 million beneficiaries would qualify for weight loss drugs in 2026. But a lot of people are switching to GLP-1s.
Lightpath Metabolic, expected to be available in 2026, will not only include programs for people with type 1 and type 2 diabetes and hypertension — as the current iteration of Onduo does — but will also offer GLP-1 drug prescriptions.
… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes. In
… Eli Lilly’s blockbuster diabetes and obesity drug improved liver scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year, STAT tells us. But the patent on semaglutide, the active ingredient in both drugs, expires in China in 2026. So no need to mess with rebates.
billion ) in 2026. However, knowing what to make of discounts from list prices ranging from 38% for Imbruvica for blood cancers to 79% for Januvia for diabetes is trickier. Those of us who work in drug pricing daily are closely examining and evaluating the methods used to determine these prices.
Jardiance, a diabetes medicine co-marketed by Boehringer, is expected to be among the first drugs to face negotiation once the law takes effect in 2026. Continue to STAT+ to read the full story…
Cipla holds a prominent position in the top five therapy areas in India, except for the anti-diabetes and gastrointestinal segment. Against this backdrop, the Indian pharma major is constantly partnering with multinational companies to get access to an innovative portfolio with a focus on diabetes, says GlobalData.
A Novo Nordisk executive believes that Ozempic, the blockbuster diabetes shot made by the company, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the Medicare program, Bloomberg News writes. The Inflation Reduction Act, which allows the U.S.
By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.
India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026.
The GIP and GLP-1 receptor agonist was evaluated over 176-weeks compared to placebo in adults with pre-diabetes and obesity or overweight. The aim of the study was to assess its efficacy and safety for long-term weight management and for delaying the participants progression to diabetes. Overall, tirzepatide facilitated a 22.9
Edgardo Hernandez , Executive Vice President and President of Lilly Manufacturing Operations, explained that the company ’s new investments will enhance production of medicines for diabetes, obesity and Alzheimer’s. Production is expected to begin in 2026.
The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity. With a projected launch in 2026, it represents Eli Lilly’s bid to expand the company’s dominance in the GLP-1R category.”
Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. Both are GLP-1 receptor agonists. Tirzepatide’s US patent lasts until 2036, with no known biosimilars, even in China.
These treatments are indicated for obesity and type 2 diabetes. Eli Lilly anticipates that medicine production at the Lebanon site will begin near the end of 2026. This new $5.3 billion investment tops the largest manufacturing investment in [Eli Lilly’s] history” This new $5.3
. “ABBV-RGX-314 [could] become a first-in-class gene therapy for wet AMD and the standard of care to treat and prevent progression of diabetic retinopathy,” stated Kenneth Mills, President and Chief Executive Officer of REGENXBIO. Regulatory submissions are expected in late 2025 through the first half of 2026, REGENXBIO confirmed.
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No.
Novo Nordisk specified that the transaction is expected to support an incremental increase in the company’s filling capacity from 2026 and onwards. Jørgensen shared that the firm is “very pleased” with the agreement, as it will allow the company to “serve significantly more people living with diabetes and obesity in the future”.
Soriot also highlighted to performance of Farxiga (dapagliflozin), AZ’s SGLT2 inhibit for diabetes, heart failure and chronic kidney disease, which made $1 billion in the quarter, with a higher-than-predicted rise of 60% over the same period of 2021.
The drug is important to Bayer as Xarelto is coming to the end of its patent life and facing the threat of low-cost generic competition starting in 2026 that will eat into its sales. All three studies are looking at the drug on its own and in combination with anti-platelet therapies like aspirin and clopidogrel.
With the promise of significant breakthroughs in treatment of diabetes, cancer, and congenital conditions, it is no wonder that research and development is predicted to reach $232.5 billion by 2026, up from $186 billion in 2019 according to the Evaluate Pharma report.
The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. The post NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule appeared first on National Health Council. link] duals-rfi/.
Based on their rising popularity to treat type 2 diabetes and obesity, GlobalData has predicted that sales of glucagon-like peptide-1 receptor (GLP-1R) drugs will increase fourfold to an estimated $142 billion by 2030. Eli Lilly shared that production of the medicines will commence at the Lebanon site towards the end of 2026.
1 And we appreciated CMS’ thorough responses to comments for IPAY 2026 and hope the Agency will replicate this for this comment opportunity. These elements were previously highlighted in our comments in response to the IPAY 2026 guidance, and we continue to stress their importance for the 2027 draft guidance.
Revenue prospects for Novo Nordisk’s blockbuster diabetes and weight-loss drug semaglutide in Brazil have been dealt a major blow after a federal court denied a request by the Danish firm for two patent extensions. Ozempic has been approved for diabetes in Brazil since 2018, joined by Rybelsus in 2020 and Wegovy in January this year.
In early 2026, Grünenthal intends to buy out the remaining stake in the JV to claim full control of the products, which include fentanyl-based products Abstral and PecFent for breakthrough cancer pain, Moventig (naloxegol) for opioid-induced constipation, and nutritional supplement Adcal-D3 for osteoporosis. billion in 2021.
Billion by 2026 with a CAGR of 37.2% This year, we are, and will continue to witness patients with chronic health conditions, like diabetes and hypertension, for example, make use of telehealth services. According to a stat by Medgadget, “Global Telemedicine Market is valued at USD 27.04 Billion in 2019 and Expected to Reach USD 171.81
Medicare currently covers the medications made by Novo Nordisk and Eli Lilly to treat diabetes and heart disease, but not for obesity alone because it is prohibited by law from doing so. Given the price tag, a bill in Congress to extend coverage has stalled for years.
Five Wall Street analysts and two investors told Reuters they expect the negotiations over prices that will go into effect in 2026 to result in cuts ranging from the statutory minimum of 25% to as much as 60% when the final numbers are set in September. The drugmakers and the government are expected to wait until then to disclose them.
Kerendia is already approved in major markets in chronic kidney disease (CKD) associated with type 2 diabetes. billion in sales by 2026. Bayer has exclusive worldwide marketing rights for this product including the U.S. The medical imaging AI market is the fastest growing segment within the global radiology industry.
Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. million patients’ journeys with type 2 diabetes since 2014.
Albutein appears to be on track to be the first therapeutic approved for DC, with a projected US launch date in Q1 2026. As such, it is unsurprising that a stem cell therapy is being considered for the treatment of DC due to NASH. tumor formation, immune reactions, and therapy failure).
Pharmacy and Therapeutics (P&T) Committee Standards: The NHC supports the inclusion of a consumer representative in P&T committees starting January 1, 2026, ensuring patient perspectives are considered in formulary decisions, decisions with patient needs and preferences.
Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).
Prevention in Public Health Pharmacists play a crucial role in primary healthcare, offering services like disease risk assessment, screening, patient referrals, disease management and medication optimization for noncommunicable diseases like cardiovascular conditions, asthma , chronic obstructive pulmonary disease and diabetes mellitus.
Live panelists included Dr. Stephen James, Director, Division of Digestive Diseases and Nutrition at the National Institute for Diabetes, Digestive and Kidney Diseases and Brenda Rodriguez, Senior Engagement Officer at the Patient-Centered Outcomes Research Institute. This year’s theme was “Improving Patient Care.”
per cent by 2026 and 37.5 billion by 2026 and $100.4 billion by 2026 and $100.4 Today, as founder of the Epygen Group, Ghosh leverages his contacts and expertise across three continents, hoping to snag a slice of the $70 billion global biosimilar pie, tapping biosimilars in the diabetes, oncology and cardiovascular segments.
This will support the development of next-generation therapies, including GLP-1 drugs targeting diabetes and obesity. Construction and infrastructure development will begin immediately, with the first supplies of GLP-1 therapies expected in 2026. We are looking forward to a bright future at Mourenx.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content